| Sector |
Miscellaneous
|
Compare with Sector peers |
| Industry |
Miscellaneous
|
Compare with Industry peers |
| Website | http://www.vantabio.com | |
| Market Cap | 34.00 Cr. | |
| Enterprise Value(EV) | 58.60 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -10.27 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 69.77 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 27.75 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 1.94 | Calculated using Price: 53.86 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.63 Cr. | 6,312,000 Shares |
| FaceValue | 10 | |
| About Vanta Bioscience Ltd. | ||
| The company is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition they also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation. | ||
| 1 Day |
|
|
| 1 Week |
|
-3.82% |
| 1 Month |
|
+28.85% |
| 3 Month |
|
-8.40% |
| 6 Month |
|
+1.89% |
| 1 Year |
|
-27.07% |
| 2 Year |
|
-48.70% |
| 5 Year |
|
-42.58% |
| 10 Year |
|
| 5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 3.14 | 4.43 | 1.89 | 0.56 | -50.31 | |
| Return on Capital Employed (%) | 7.87 | 8.62 | 5.42 | 4.00 | -6.10 | |
| Return on Assets (%) | 1.78 | 2.31 | 0.76 | 0.18 | -12.57 |
| Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 22 | 23 | 24 | 24 | 18 | 17 | |
| Non Curr. Liab. | 13 | 14 | 29 | 38 | 48 | 47 | |
| Curr. Liab. | 3 | 10 | 15 | 14 | 18 | 18 | |
| Minority Int. | 1 | 1 | 2 | 5 | 1 | 2 | |
| Equity & Liab. | 39 | 49 | 70 | 81 | 85 | 85 | |
| Non Curr. Assets | 22 | 29 | 50 | 67 | 69 | 69 | |
| Curr. Assets | 17 | 20 | 20 | 15 | 15 | 15 | |
| Misc. Exp. not W/O | |||||||
| Total Assets | 39 | 49 | 70 | 81 | 85 | 85 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 12 | 14 | 10 | 10 | 6 | |
| Other Income | 0 | 0 | 0 | 0 | 1 | |
| Total Income | 12 | 14 | 10 | 10 | 7 | |
| Total Expenditure | -9 | -9 | -6 | -6 | -9 | |
| PBIDT | 4 | 4 | 4 | 4 | -2 | |
| Interest | -2 | -2 | -2 | -2 | -6 | |
| Depreciation | -1 | -1 | -1 | -1 | -3 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | ||||||
| PAT | 1 | 1 | 0 | 0 | -10 | |
| Minority Interest | 0 | 0 | 4 | |||
| Share Associate | ||||||
| Other Related Items | ||||||
| Consolidated Net Profit | 1 | 1 | 0 | 0 | -6 | |
| Adjusted EPS | 1 | 2 | 1 | 0 | -10 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -1 | 2 | 7 | 5 | -1 | |
| Cash Fr. Inv. | -6 | -7 | -22 | -17 | -6 | |
| Cash Fr. Finan. | 10 | 2 | 18 | 9 | 6 | |
| Net Change | 3 | -3 | 2 | -2 | 0 | |
| Cash & Cash Eqvt | 3 | 0 | 3 | 0 | 0 |
|
Tue, 14 Nov 2023
Change In Designation Of Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757) From Whole Time Director To Non-Executive Director W.E.F 14.11.2023. Change in Designation of Dr. Vyasmurti Madhavrao Shingatgeri from WTD to Non Executive Director w.e.f 14.11.2023 |
|
Tue, 14 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.11.2023 Outcome of Board Meeting held on 14.11.2023 |
|
Wed, 08 Nov 2023
Board Meeting Intimation for Approval Of Unaudited Financial Statements For The Period Ended 30.09.2023 Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve the un-audited financial results of the Company for the half year ended 30.09.2023 and to take note of the Statutory Auditors limited review reports thereon. |
| Wed, 22 Nov 2023 |
Opening at Low
|
Closing Above Previous High
|
Close Below Last Week Low
|
Close Above Last Month High
|
High Increase in 1 Month
|
Equities
M.F.
Sectors
StockEdge Social